Gregor founded Pharmacentric Solutions Ltd in 2017 to deliver consultancy services for the Pharma Industry specialising in device and packaging development and strategies from early concept through to commercial supply. Prior to this Gregor was Senior Design Director at GSK working as a device and packaging specialist and has over 30 years’ experience in Pharma and Medical Device design and is a named inventor on over 40 patents and has presented widely on topics such as Digital, Patient Centric Design and Pharma road mapping. He has a B.Sc. in Industrial Design and a M.Sc. in Polymer Science and Engineering. After 3 years at Smiths Medical Systems he joined the Device Development Unit at GSK R&D. He led platform developments including injectable and respiratory devices. In 2009 Greg moved to GSK Manufacturing as Global Head of Technical Packaging. In 2017 he authored the Technology and Innovation road map for UK Pharma.
Aurelio is a global thought leader based in IQVIA’s London office. The European Thought Leadership team creates topical and forward-looking strategic content relevant to pharma executives worldwide and publishes articles, blogs and white papers on a regular basis.
Aurelio’s predominant focus is on off-patent markets where he generates evidence-led insights with a view to spark high-level discourse in established brands, biosimilars, generics and value-added medicines. He is considered a subject matter expert in these areas where he speaks at numerous conferences worldwide, presents at board-level meetings and engages in consulting projects in an advisory capacity.
Prior to IQVIA, Aurelio has worked in Discovery R&D and as a strategy consultant in Life Sciences. He holds an MSci in Chemistry from Imperial College London.
Philippe Arnaud is a pharmacist, Professor of the University, in the field of Pharmaceutical Sciences at the Faculty of Pharmacy of Paris and a Hospital Practitioner at the Public Assistance Hospitals of Paris.
He also taught during 10 years at the Faculty of Pharmacy of Rouen, and was a visiting Professor at University Laval, Quebec, Canada. He has been for more than 25 years an expert at the French Health National Agency ANSM for the pharmaceutical part of the AMM both in the field of originators, generics, allergenic products and biotechnology and was at the birth of Pharmapack and chaired the price jury. It accompanies the pharmaceutical development of a drug or a medical device and its packaging. He was for 10 years president of a trade union of hospital pharmacists the SNPHPU. He is member of the French National Academy of Pharmacy.
He is the author of more than 200 publications and communications in the field of pharmaceutical sciences as well as hospital pharmacy activity and market access.
Chris holds an Honors degree in Mechanical Engineering. For the last nine years Chris has been located at Aptar Pharma’s manufacturing facility in Le Vaudreuil, Normandy where he oversees the global business development activities for Aptar’s inhalation drug delivery devices (MDI & DPI) and their respective services pertaining to the application fields of Asthma & COPD.
Chris has 28 years’ experience working in the field of Inhalation Drug Delivery (IDD) with significant expertise associated to metering valve technologies for pMDIs and their accessory / peripheral device technologies, including dose indicators and Breath-Activated Inhalers. Over the latter 6 years, Chris also took responsibility for Aptar’s Dry Powder Inhaler technologies.
Chris previously worked at 3M Health Care (Drug Delivery Systems Division - UK), for 19 years, holding various positions and responsibilities within 3M’s R&D (Valve Development Specialist), Manufacturing (Manufacturing Technology Leader), Six-Sigma (Site Coach), Technical Sales and New Business Development functions. During this period Chris was closely involved in the development, optimization, commercialization and sale of IDD componentry (valves, canisters and accessory devices) for several innovator pMDI products.
Markus is a Director at SHL Group. He investigates the market for connectivity and emerging technologies in the fields of secondary packaging and drug delivery devices.
Markus has over 15 years' experience in pharmaceutical packaging, leading in various roles such as global key account management, research and innovation and business development. Markus ran a technology startup, ConnectMeSmart, over the last four years working closely with and for SHL. His work has looked into the application of new technologies such as smartphones, mobile apps, and connectivity. He also worked for Schreiner MediPharm between 2004 and 2014, and is the co-inventor of Needle-Trap, a label integrated needlestick prevention solution.
Markus studied process engineering at the Technical University of Clausthal and started his career in environmental and recycling technology at RWE in Germany in 1997 prior to moving to the pharmaceutical industry.
Sagar Bejalwar is Global Portfolio Lead at BD Pharmaceutical Systems, where his responsibilities include developing ready to administer prefillable solutions that most closely address drug manufacturer and clinician needs. Mr Bejalwar holds an MBA from Texas Christian University (Fort Worth, TX, US) and also a Bachelor’s degree in Electrical Engineering from the National Institute of Technology, India.
Frédéric Bertaïna is the CEO of Bioxis Pharmaceuticals, a French Medical Device startup focusing on biopolymers for their use in cosmetic surgery.
Over the last 5 years, Frédéric raised over 10M€, launched his company’s first product (generated 2M€ sales on the first semester after launch) and plans are in place to start a new phase 1 clinical trial in Q1 2020 for the revolutionary technology MTI12.
Frédéric graduated with an MSc in Strategy and Healthcare Management from ESSEC business school, in Project Management & Geopolitics from University of Paris Est and followed several trainings in Pharmaceutical Development at Kings College London.
Guillaume Bonafous holds a bachelor of engineering in aerospace engineering design at Kingston University (London) and a master degree in Industrial and Production engineering from Ecole des Mines d’Albi.
He began his career at Sanofi Montpellier in 2007 as method engineer, in charge of the implementation of tools for continuous improvement in the production area. Five years later, Guillaume became a Clinical Packaging Manager in charge of the design, the supplies and the management of the clinical packaging campaigns. Since 2017 he works for the industrial Development department of Clinical Supplies Chain in Montpellier. He accompanies the Packaging project manager in the design of complex and innovative packaging.
Nicolas Brandes has worked within the pharmaceutical packaging industry for almost ten years in areas of business development, research & development, technical services and marketing.
Currently in his role as Director Global Product Management, Nicolas is responsible for defining new market requirements, launching new products, supporting business development plans, and overall execution of global marketing strategies, all related to West’s portfolio of polymer container solutions.
Dr. Brandes received his Ph.D. in Biology from the University of Wuerzburg, Germany, after performing his research studies at the University of Michigan, USA.
1982 Pharmacist degree option Biology, Paris X
1986 Official Bernay installation 27300.
1989 Election to the CROP - Regional Council of Pharmacists of Upper Normandy
1991 Founder of Pharma Reference (PHR Group), group of community pharmacists
CEO of the PHR Group.
1998 Expert at Afssaps: National Commission of Material Safety and AMM Commission GT CPD - Expert at ANAES and DHOS, group: Chemotherapy at Home.
Founder and President of HOPADOM, network of health professionals for the sick at home, Upper Normandy
2001 President of CROP Haute Normandie. Member of the Central Council Office of
the Order of Community Pharmacists. CCA.
2003 Expert at CNIB: Home Chemotherapy.
As a pharmacist and after two previous professional experiences : the first in a pharmaceutical firm and the second in the French Authorities, I have almost 20 years of experience in the Leem in the field of pharmaceutical quality. As Pharmaceutical Affairs Director, I have the leadership for responding to enquiries and needs in various domains as quality regulation, bioproduction and biodevelopment regulation, management of the pharmaceutical sites and activities of the responsible pharmacist and thus to fulfil the role of interlocutor between the Pharmaceutical Industry and the National Authorities, and particularly with the inspection of ANSM (the French Medicines Agency) or with the Health Ministery. Otherwise I work every day with sister-Associations.
The Leem is the French pharmaceutical Industry Association and federates more than 95 per cent of companies in France. Its main role is to act as a coordinator between its members to better influence the pharmaceutical environment, in its large expertise field: scientific, legal, economic, industrial, training, communication.
Dr Alex Cole gained a PhD in solid state physics from the University of Leeds in 2004, he worked in photovoltaics research followed by photonics based medtech before joining CPI in 2017. Dr Cole is part of the Strategic Marketing team within the remit of printable electronics for smart supply chains and smart pharmaceutical packaging. He recently led an initiative to understand the capability requirements for a centre of excellence in smart pharma packaging. He is currently leading the CPI Strategic Marketing Smart Packaging Initiative and is keen to help support the development and scale up of innovations that will improve supply chains, reduce waste and improve patient outcomes.
Graduating as a pharmacist in 1989, Isabelle Debrix oriented her career towards hospital pharmacy. She was appointed Hospital Practitioner in 1995 at Hospital Tenon where she then served as the Pharmacy Department Head from 2009 to 2014. Presently Dr. Debrix manages the Medication Department for the Eastern Parisian Hospital Group including hospitals Saint Antoine, Tenon, Trousseau, Rothschild and Laroche Guyon.
Earning her PhD in 1994, Dr. Debrix pursued studies in medical and biological ethics and focused her research on the medical guidelines and proper use of oncological medicines. Part of this work was the subject of her 2002 post doctoral dissertation. She is the author or co-author of 24 international publications.
Dr. Debrix continues to engage in research and encourages the involvement of her team to evaluate professional pharmacy practices and develop innovative methods.
Her current research topics focus particularly on securing the delivery of medication to patients.
Christian Dechant brings more than 18 years’ experience in various roles to the primary packaging development department at Boehringer Ingelheim.
At BI microParts GmbH, he started working in research & development of microfluidic systems and was later responsible for the implementation and running of clinical trial manufacturing for Devices (e.g. Respimat).
In 2010 he started working at Boehringer Ingelheim as a primary packaging engineer with a focus on liquid formulations for parenteral and oral solutions. Since 2014 he is responsible for the primary packaging development group for parenteral solutions within Pharmaceutical Development Biologicals. He established the primary packaging development group with a focus on NCE and NBE development. In this role he is responsible for the selection of suitable container closure systems to ensure the stability of the formulation and the functionality within a combination product like an autoinjector.
Christian Dechant holds a Diploma degree in industrial engineering from the University of Applied Sciences of Bochum, Germany.
Martin Folger is currently (since September 2018) Head of Risk Management Sciences, Compliance and Quality within the global function Pharmaceutical Sciences at Boehringer Ingelheim Vetmedica GmbH. He is a pharmacist and holds a PhD in Pharmaceutical Technology from the Technical University of Braunschweig, Germany. After starting his career working in pharmaceutical manufacturing of oral solid dosage forms for two years for a major US-based pharmaceutical company, he joined the Animal Health business of Boehringer Ingelheim in 1997 as a manager in formulation development. From 2002 until September 2018 he was Head of Global CMC Development Pharmaceuticals and responsible for all CMC-related activities including e.g. packaging development. He currently also has the role as the Qualified Person for investigational veterinary product.
Frédéric Gabriel is Chief Innovation Officer for the Haselmeier Group and General Manager of Haselmeier Switzerland. He oversees strategic innovation activities as well as product innovation, pre-development, product and IP portfolio management, as well as licensing activities. Frédéric Gabriel joined Haselmeier in 2008 and was responsible for the Project Business. Prior to Haselmeier, Frédéric Gabriel worked as Business Analyst at Capgemini in the European Biotech Group in Stuttgart before joining Genzyme (now Genzyme-Sanofi) in 2005. At Genzyme, he worked as Business Analyst and later as Program Manager for the European Cardiovascular Business Unit, responsible for the European launch of Genzyme’s first cardiovascular product. He holds a MSc in Biology from the École Normale Supérieure in Paris and a M.B.A. from the European School of Business, ESCP-EAP.
Stefan Gaul has deep knowledge and insight regarding the development and successful implementation of new and innovative products. He was already active in various business areas, focusing on product innovation, strategic positioning, project management and market implementation. Stefan joined Haselmeier in 2014 and took over the responsibility for the “Strategic Product Management” in 2016. Stefan has a strong patient-centered approach which drives product definition, roadmap and development. His current role accounts for the whole journey of a new and innovative product: from thorough market analysis and the identification of market opportunities through the product definition and execution of innovation projects to proof of concept of the various programs. Previously, Stefan did hold several positions as Global Product Manager, Project Manager, Head of Development at SIG, Schöttli and did set up his own business for innovation, design and development.
Pr Anne Gayot, Pharmacist, co-charge of the Pharmaceutical Industry Laboratory at the University of LILLE-France, member of the French Pharmaceutical and Generic working group of ANSM
Professor Anne GAYOT is in co-charge of the Pharmaceutical Industry Laboratory at the University of LILLE-France.This laboratory, beyond its teaching activities in the field of the development and production of pharmaceutical products, studies the solid state properties and properties of the particulate solid of the raw materials used in the formulation of drugs.It studies the physical properties of excipients and active substances with respect to functionnality characteristics.Professor Anne GAYOT was until reorganisation of the french agency member of the French Marketing authorization committee She is now member of the French Pharmaceutical and Generic working group at the French Agency. She participates to the writing of the guideline on Pharmaceutical Development of Medicines for Paediatric Use. She is the chair of the Functionnality Group related characteristics of the European Pharmacopoeia.She prepared her phD at the University of Lille (1981). It concerns microcapsules of activated charcoal for renal patients.Her scientific work concerns chacterisation of solid particles, extrusion-spheronisation, powder for inhalation. She is in charge of the master in industrial pharmaceutics.
Noel Gibbons BSc (Hons) is the Technical Advisor for Medical Device and Pharmaceutical packaging within STERIS AST. He has significant experience in a wide variety of areas from manufacturing, process validation, package testing, packaging process validation, package integrity testing, quality and international test standards. He has significant practical experience in medical device packaging at all levels, including evaluation of proposed packaging and current packaging designs and related validation documentation.
Noel has presented numerous seminars nationally and internationally on Medical Device and Pharmaceutical package testing particularly on the requirements of the ISO11607 and associated test standards.
Daniele has over 10 years’ experience of purchasing in Global Pharmaceutical Manufacturing and Supply Chain environments. He has held roles with increasing responsibility in multiple locations across Europe. At Abbott Laboratories, he enhanced his procurement expertise and pharmaceutical knowledge while based at a manufacturing plant in Italy, in the divisional offices in London & Dublin and also in the headquarters in Basel.
Daniele joined Ferring HQ near Lausanne (CH) in October 2013 as Global Category Manager, in charge of the global purchasing strategy and its execution for key packaging materials and medical devices used in Ferring Finished Products.
Daniele was appointed Head of Purchasing, Solids and Packaging Cluster in February 2017 and Director of Product Supply Direct Procurement in November 2017.
Daniele has a Masters Degree in Industrial Engineering from the University of Rome, Italy, followed by an MBA at the UCD Michael Smurfit Graduate Business School, Dublin, Ireland.
Mr. Golfetto is the Drug Delivery Systems Business Development Director of Stevanato Group.
He manages all new product design, testing and development activities starting from the initial Customer requirements to the final industrial product validation, with the coordination of many experts in glass technology, process engineers and designers. The Team managed by Mr. Golfetto is also responsible for engineering support and assistance related to technical or process issues on the Customer’s side. Member of PDA, Mr. Golfetto provides presentations and lectures for healthcare industry Organizations and Associations; furthermore, he is the author of some papers for important magazines in the field.
Formerly Mr. Golfetto was the R&D Manager of the Appliances Engineering Team within a well known worldwide manufacturer of household appliances. During his latest years of employment in this position, he was in charge of the harmonization team, made up of local engineers and designers, responsible for moving the Company’s production plants to Guangdong, China.
As a Member of the European Electro-technical Commission until 2005, Mr. Golfetto contributed in the development of European Norms and Regulations focused on user safety and environmentally friendly consumer products.
Carole Grassi has a long experience in the packaging industry, she spent more than 13 years in the beauty, pharmaceutical and consumer goods packaging at Albea group (previously Rexam). She held several positions in strategy, business development and marketing before she joined SGD Pharma in 2017 as VP Marketing & Communication and is appointed Chief Innovation & Development in 2019. One of her key achievement was to reinforce SGD Pharma’s innovations, particularly with the development and the launch of the Ready-To-Use offer Sterinity.
Marrie Groeneveld is the CCO of SkyCell, the 4th largest pharma airfreight container provider with the mission to supply the safest pharma containers worldwide. He has a 30-year track record of successful experience in the contract logistics and healthcare supply chain industry with some of the largest international logistics companies, such as DHL, UPS, Movianto and Expeditors, where he served in several senior and executive positions. Marrie is an acknowledged specialist in supply chain solutions and end-to-end solutions for the healthcare, pharma and biopharma industries.
Michael is the Co-Founder of Anteris Medical. He is a medical device professional with more than 14 years’ experience in mid-size and global biotech and device organizations in the fields of development, quality and regulatory affairs including Electrical Medical Devices (class II and III) comprising sw, electronics hw, Medical Software Products and Drug Delivery Systems for biologics (Autoinjectors / Needle Safety Devices).
Michael is a certified lead auditor for ISO 13485 (British Standards Institute) and leads the set up of ISO 13485 QM systems within organizations ranging from start-ups to global pharma companies. He was involved in International Project Management for various Medical Device Development Projects from Kick Off till Commercialization (EU / US / Asia) and is an expert in US and EU compliant processes for Requirements Engineering, Verification / Validation, Usability and Risk Management.
He has a strong focus on Design Control, Regulatory Affairs and Quality Management for combination products and stand-alone medical devices.
Arnaud Guillet is Business Development Director at Biocorp, in charge of finding partnerships and license opportunities for Biocorp’s range of connected devices. Previously, Guillet worked for a healthcare consulting firm with a strong focus on connected health strategies for pharma and insurance companies and has additional past experience in the pharmaceutical industry (with Sanofi) and the insurance industry (with AXA). He graduated from HEC Paris, a major European business school.
A pharmacist specializing in regulatory affairs, access to the market and reimbursement of innovative medical technologies, he accompanies these companies on the French and international markets.
After starting his career as a university lecturer and researcher, he joined the pharmaceutical industry, then the world of medical devices, in international companies and professional associations, where he held various management positions, notably in Research & Development, Regulatory Affairs, Quality Assurance and Market Access as well as Medico-Economic Evaluation.
Dr. Matthew Hall is Applications Engineering Manager for Corning Pharmaceutical Technologies. He was previously an Associate Professor of Biomaterials & Glass Science and Director of the Center for Advanced Ceramic Technology at Alfred University. Dr. Hall holds MS and PhD degrees in Glass Science from Alfred University and a MBA degree from the Simon School of Business at the University of Rochester. His technical areas of expertise include specialty glass processing and medical applications of glass technology.
Badre Hammond’s background is in Biochemistry, with 14 years’ experience in pharmaceutical product development with focus on nasal and pulmonary drug delivery systems. Mr. Hammond has broad experience in managing the development of novel drug product programs for the pharmaceutical market from formulation development, pre-clinical, and CMC to clinical phase.
Nanja leads strategic environmental initiatives within the Circular for Zero strategy. She leads the implementation of circular thinking in product design enabling the change to sustainable materials and design for recycling. Moreover, she drives initiatives to engage employees across Novo Nordisk in the implementation of Circular for Zero.
Nanja is an environmental engineer and has extensive experience with life cycle assessment, circular economy and waste management. Before joining Novo Nordisk in 2013, she worked for 7 years as a consultant.
Dr. Andreas Hofenauer is Manager Innovation and Strategic Partnerships Healthcare at Schreiner MediPharm, a business unit of Schreiner Group GmbH & Co. KG. Schreiner MediPharm develops and produces innovative, multi-functional specialty labels with value-added benefits for the pharmaceutical industry. Andreas is in charge of identifying new product solutions that are optimally tailored to specific market and customer requirements and is responsible for strategic partnerships with companies in the pharmaceutical packaging sector. Prior to joining Schreiner MediPharm in 2013, Andreas worked as department head in the paper industry in the field of innovation for several years. He graduated and received the doctoral degree in natural sciences at the Technical.
Peter began his career in the early 1980’s at Witt Plastics, selling various types of polymeric raw materials (film, sheet, and synthetic resin) to the medical, pharmaceutical and electronics industries in Puerto Rico and throughout the Caribbean. Polymerland acquired that business segment in 1990, and his geographic responsibilities expanded to include Mexico and Central America. Peter was a founding member of the local branch of the Society of Plastics Engineers (SPE) in Puerto Rico.
In 1994, Peter joined American Mirrex (formerly American Hoechst, a major supplier of PVC film to the healthcare industry at that time), where he was Product Manager and then Director of Marketing. While at Mirrex, he was part of the executive committee that turned around the business and resulted in the successful sale of the company.
In 1996, he founded Montesino Associates to provide consulting services to the healthcare packaging industry in regulatory, technical, M&A and marketing areas. Montesino from 1998 - 2008 was a manufacturer's representative for high technology film processing and converting equipment. Over the next decade, Montesino mapped connections, channels, and opportunities,bringing together polymers and packaging manufacturers with healthcare producers. Whether introducing barrier materials to healthcare in South America or supporting the entrance of engineering materials to healthcare producers, Peter continued to develop links and connections between disparate markets and geographies to create value and solve problems.
Peter and Montesino continue to work in understanding the interconnections between polymer and packaging manufacturers and processors, global geographies and emerging marketplaces, and the healthcare marketplace. Peter is an active member the Society of Plastic
Engineers (SPE) and the International Organization of Packaging Professionals (IOPP).
Lionel Jeannin is an Arts & Métiers ParisTech Engineer with a Master degree in Business Administration from IAE Aix-en-Provence. He has more than 17 years’ experience in the Medical Device and Pharmaceutical industry. He held Project Manager and Development Team Manager positions in the Industrial Engineering, Medical Devices for eye surgery, Parenteral Nutrition and OTC/Rx Pharmaceutical domains. He had the Global responsibility of Packaging Development for OTC Brands like Voltaren, Nicotinell and Fenistil and is currently in charge of Device & Packaging Development projects for new oral medications at Novartis Pharma AG. He is also a member of Novartis Pharma Drug Delivery e-Device / Digital Development network.
After completing his Ph.D. in Chemistry, Dr. Daniel Keesman has been working for more than 25 years for pharmaceutical supplier industry.
Starting his career as Key account Manager with MDL Elsevier, San Leandro/USA, he finally managed the whole business and operations with locations in Europe as Vice President and General Manager.
In 2001 he continued his professional activities as Chief Operating Officer and co-CEO with Lion Bioscience AG in Heidelberg, where he was responsible for all businesses and operations.
Since 2009 Dr. Keesman has been managing the August Faller GmbH & Co. KG as President and Managing Partner. Faller is a medium-sized group of companies for pharmaceutical secondary packaging with 4 sites in Germany (Waldkirch (with HQ), Binzen, Schopfheim and Grossbeeren) and 2 European sites in Copenhagen (DK) and Lodz (PL).
Fran DeGrazio has more than 35 years of experience in the pharmaceutical packaging and delivery industry, with extensive expertise in injectable drug products, including vial container closure systems and prefillable systems used for combination products. Fran has spent time in numerous technical roles, including R&D, Quality & Regulatory, Technical Support and Analytical Laboratories. Today, she is Vice President, Scientific Affairs & Technical Services for the West enterprise. This role is focused on assuring West’s scientific industry leadership as they innovate new products and services for the market.
Jason Lacombe is the CEO of Veratrak, a software company purposely built for the pharmaceutical supply chain, facilitating secure documents and master data collaboration for its partners. Jason first became interested in blockchain technology while studying a PhD at the University of Oxford, where held an executive role on the blockchain society. In a past life, Jason had exposure to the pharmaceutical industry as an Expert Advisor to the European Parliament, member of a World Health Organisation Collaborating Centre, and as a health economist. Most recently, Jason was selected to the Forbes 30 Under 30 and as a blockchain influencer in a report led by the UK All Party Parliamentary Group on Blockchain.
With a Master’s Degree in Chemical and Process Engineering at the University of Padua, Martina Largoni boasts a vast knowledge in chemistry, physics, informatics, mathematics and statistics. She worked on the optimization of pharmaceutical processes, engineering the monitoring and control of the quality of the product. She entered Stevanato Group in 2015 as Technical and Quality Assurance Front End for Ompi, gaining experience in the glass primary packaging and injectable delivery fields. Now she is Product Manager for Vials.
Thierry co-founded Kurma in 2009. He has 25 years of experience in the Life Science Venture industry and is a Pharmacist and PhD by training. Thierry started his career in Japan as a scientific representative for Laboratoires Fournier (1992-1996). Having then studied at Insead, he joined Flamel Technologies as project director for Pharmaceutical R&D, after its IPO on the Nasdaq (1997-1998). He then moved to the investment world, first at Caisse des Dépots (1998-2005), then to AGF Private Equity (2005-2009), where he supervised the healthcare investment team. Thierry led investments in companies like Actelion, Arpida, Targacept, Adocia, Auris, Erytech or Safe Orthopaedics. He is currently on the Board of Directors of Meiogenix, Pathoquest, Blink Biomedical, Asarina Pharma and Minoryx.
Franck Lescure is Partner in charge of Life Sciences investments at Elaia Partners. Until 2018, Franck was Partner in charge of Life Sciences activities at Auriga Partners. Between 1990 and 1995, he has participated to the initial years of Genset, one of the first French biotech startups. Between 1997 and 2002, he joined the Air Liquide group in its healthcare subsidiary, followed by 2 years as member of the Venture Capital team of Crédit Lyonnais Private Equity. Franck Cumulates 28 years of experience in technology innovation, including 17 years in Capital Venture. He notably led investments in TxCell, Median or Erytech and he is currently on the board of directors of Amoeba, Enobraq, Fabentech, Flash Tx, Nosopharm, Pherecydes and Pylote.
Franck is an alumnus of the Ecole Normale Supérieure and of the Institut Pasteur. He holds a PhD in Microbiology and Virology and a MBA from the Collège des Ingénieurs.
Takuya Minezaki joined Mitsubishi Gas Chemical in 2005. He specializes in the field of polymer. Since 2017, he has worked in the project of new pharmaceutical containers by utilizing oxygen absorbing resins. Also he is in charge of the development of secondary materials, such as plunger stopper and top cap. He holds a Master of Engineering in Applied Chemistry from the University of Tokyo.
Pierre obtained his Ph.D. in Polymer Chemistry from Carleton University in Ottawa (Canada). For over 20 years, Pierre Moulinié has occupied various technical roles to support Polycarbonates at Covestro. Today, he is the Global Technology Lead for Healthcare in the Polycarbonates Business Unit. He remains active in the Society of Plastics Engineers and is the Medical Plastics Division Past-Chair.
Wenzel studied biology, and did his PhD in physics at the Max-Planck-Institute for Neurochemistry in Munich. As head of laboratory in a Swiss biotech-company, he worked on Keratinocytes. In charge of project management and as head of production for presterilzed syringes, he designed the manufacturing area and operated the production start-up phase. He took the role of Chief-Innovation-Officer at a pharmaceutical equipment supplier. While two years in the USA, he developed the market for cell- and gene therapy equipment. In 2018, he returned to the same primary packaging manufacturer he left 13 years ago in a new global senior role for business development.
Tom leads engineering and scientific teams developing new injection devices, pumps and inhalers. He has been the named inventor on dozens of patents throughout his 20 years’ experience in the industry.
He is a regular speaker at various international conferences on innovation and medical device development, and mentors Engineering and MBA students on innovation and device development at the Cambridge University Engineering Department and the Judge Business School.
He read Engineering at Cambridge University before becoming the Choate Fellow in Human Physiology and Pathology at Harvard University.
Corinne Ondo leads the sourcing strategy of glass primary containers for Merck Healthcare and through her team, she also coordinates the procurement of secondary packaging activities for various manufacturing sites in Europe and Latin America.
Before joining Merck in 2015, she had over 20 years of international experience in the luxury business, consumer goods, automotive and oil & gas industries.
She is an engineer, graduated from French ESIGELEC Graduate School of Engineering.
Mayur is an accomplished leader with over 18 years of innovative medical device development experience. He:
• advises medical device and pharmaceutical companies on innovation, technology strategy, product development and commercialisation aspects
• leads turnkey product development projects
Delphine Pernot holds a degree in agricultural engineering from AgroParisTech and a Master's degree in engineering and environmental management from ISIGE Mines Paristech. She began her career at AirParif, monitoring air quality before joining Deloitte in 2010 as a Sustainable Development consultant. Seven years later, Delphine Pernot joined Adelphe, EPR scheme for packaging in France, which deals specifically with pharmaceutical packaging. Her mission is to help clients in improving their packaging environmental footprint through building strong partnerships with stakeholders.
Anne-Catherine is dual qualified as both a pharmacist and a lawyer, specialising in pharmaceutical issues. She has in particular significant expertise on regulatory matters such as clinical trials, marketing authorisation, pricing and reimbursement, advertising. She also assists pharmaceutical companies in product liability cases, contractual or litigation arising from unfair competition. She also has experience in regulatory issues related to medical devices and food supplements. Anne-Catherine is a Senior Lecturer (professeur agrégé des universités) in pharmaceutical law at the University of Lille and directs a Masters degree in regulatory affairs.She is the author of La responsabilité du fait des médicaments. L'industrie pharmaceutique face à la loi du 19 mai 1998 (Medicinal Product Liability : the pharmaceutical industry and the law of 19 May 1998) and frequently publishes articles in national and international legal reviews on various subjects such as pharmaceutical liability, patients’ rights, clinical trials, pharmaceutical regulation, pricing, legal issues resulting from biotechnologies and the use of digital media. In December 2012 Anne-Catherine was awarded the French National Order of Pharmacists prize for her research into the liabilities of the pharmaceutical industry.
Juha-Pekka Pöyry has 10 years of experience in polymeric materials in R&D, product development and process engineering. He has worked 7 years in start-up and early-stage companies developing silver-containing polymeric antimicrobial additives and is a co-inventor on two related patent applications. Since joining DuPont, he’s responsible for technical marketing of Tyvek® product portfolio for Healthcare packaging and is an active member in the Healthcare Plastics Recycling Council in Europe. Juha-Pekka holds a master's degree in materials science from Tampere University of Technology in Finland.
Marc holds a Master's degree in English and Biology from the Ruhr University in Bochum (Germany) and a Ph.D. in Pharmaceutical Technology from Heinrich Heine University in Düsseldorf (Germany).
He started his career in the pharmaceutical industry in 2001 in Germany, as Project Manager in Regulatory Affairs for Respimat® Soft Mist Inhaler at STEAG microParts GmbH. From 2004 to 2011, Marc held increasingly senior positions in the development of inhalation devices and formulations at Boehringer Ingelheim. In 2012, he joined the Biopharma division of Boehringer Ingelheim as Senior Manager, Technology and Innovation, before being appointed Head of Device Development and Combined Products for biopharmaceuticals in 2014. In July 2017, Marc joined Novartis Pharma AG as Head of New Technology, Device Development and Marketing within TRD.
Mathias Romacker is Senior Director, Device Strategy at Pfizer HQ in New York City. He joined Pfizer in March 2015. In this role within Pfizer Global Supply he focuses on the front end of device technology. He works with multiple functions and sites across the organization to develop a device strategy for Pfizer pipeline and inline products.
Previously Mathias worked over 9 years in the device area for Amgen in Thousand Oaks, California.
Before joining Amgen he held multiple sales and marketing positions with Becton Dickinson and Gerresheimer in Germany, South Africa and New Jersey.
Mathias holds a masters equivalent degree in economics from the University of Freiburg/Germany.
Professor in Biochemistry and Molecular Genetics (Johannes Gutenberg-University of Mainz); IP Manager, Technology Transfer & Licensing (IMG GmbH, University of Mainz); Midas Pharma GmbH, since 2006: Head of IP Management, Director Custom Synthesis & Biotechnology; Current Position: Director Corporate Project Management with Focus on Primary Packaging and Injection Devices for Biotherapeutics
Andreas holds a degree in Chemical Engineering with a course specialization in Technical Chemistry. After gaining professional experience in R&D as a laboratory engineer he took the role of Manager Development Material Testing, where he was in charge of developing sealing materials for several market segments including Food & Beverage and Life sciences.
For the last 5 years he has been working with Trelleborg Sealing Solutions headquartered in Stuttgart in the role of Technical Manager responsible for the Healthcare & Medical market segment. In that capacity he leads a team of project engineers within the Healthcare & Medical Lead Group Europe working on the realization of Healthcare & Medical projects on a European level.
Paul studied chemistry followed by a PhD in physical chemistry at the University of Basel. He held various management functions with increasing responsibilities in international pharmaceutical companies for the development of oral drug products and drug/device combination products for inhalation or subcutaneous injection. Paul joined Sensile Medical three years ago and has been responsible for Business Development and Commercial.
Gautam Shetty is the founder of Congruence Medical Solutions, LLC based in Baltimore Maryland USA. Prior to Congruence Medical Solutions, Gautam was General Manager of the Novel Drug Delivery Systems business unit at Unilife Corporation. He pioneered development of ophthalmic drug delivery devices and targeted organ delivery systems. Prior to that, Gautam was with Becton Dickinson & Co. (BD) where he held a number of positions involving R&D, Strategic Marketing, Commercialization Planning and M&A. Gautam holds a PhD in Biomedical Engineering from Case Western Reserve University. He has authored several patents in the injectable drug delivery device space covering ocular drug delivery systems, novel delivery systems, pen injectors and patch pumps
Dr. Fabio Silvestri received his Laureate and PhD in Materials Science from University of Milano- Bicocca. After several academic and industrial research experiences, working mainly on the development of functional structural materials, he moved towards market and customer experience, working as a product development manager and innovation manager. He is currently Head of Product Strategy and Planning at Bormioli Pharma where he and his team, in close collaboration with R&D and the global sales network, are developing new solutions for the pharma industry.
Michael Song is the head of Biologic Device Functionality, Safety and Digital Connectivity within AstraZeneca Biopharmaceutical Development. In his current role, he oversees device functionality and safety; primary container science and technology; biocompatibility; container closure integrity; and digital connectivity development. Prior to his current role, Michael was head of the Device, Packaging, and Process Engineering department at Adello Biologics (part of Amneal Pharmaceuticals). He has held key technical positions at Stryker, Amgen, and Kavlico Corporation. Michael has led the development of both combination products as well as 510(k) medical devices. He received his postdoctoral training at Barrow Neurological Institute / St. Joseph Hospital and Medical Center (part of Dignity Health) and holds a BS in Electrical Engineering from Purdue University and PhD in Neuroscience and Toxicology from Iowa State University.
Julie D. Suman, R.Ph., Ph.D is the Founder of Next Breath, an Aptar Pharma business, and serves as its President. Dr. Suman holds a B.S. in Pharmacy from Duquesne University (1996) and a Ph.D. in Pharmaceutical Sciences from the University of Maryland, Baltimore (2002). She is a co-editor for Respiratory Drug Delivery Proceedings, an international symposium, and an Affiliate Assistant Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University. Dr. Suman is the Past-Chair of the AAPS Inhalation Technology Focus Group. She is also a licensed Maryland pharmacist. Dr. Suman has published her research in peer-reviewed journals and has been presented during podium sessions at international meetings, the FDA Visiting Professor Lecture Series and has been an invited speaker at ANVISA in Brazil. Dr. Suman’s doctoral research, which focused on the relationship between in vitro tests for nasal sprays and in vivo deposition, has been recognized for excellence by a research award presented at the International Society for Aerosols in Medicine, 2001.
Packaging engineer by training, I developed packaging for new Merck products for 10 years before joining the Corporate Responsibility group in 2015.
I am in charge of enhancing product and packaging sustainability across the Life Science division of Merck, managing and enhancing its Design for Sustainability program, creating awareness across all business areas and supporting project teams throughout the product development process. I am responsible for helping project teams identify environmental hot spots and opportunities for improvement, defining project objectives and articulating customer demands. I am also enhancing packaging sustainability by defining and implementing global packaging sustainability strategy and objectives — developing sustainable packaging guidelines, and enhancing and creating packaging recycling programs.
Yves Th. Tillet is a doctor in pharmacy, graduate of physiology and biochemistry, of the Business Administration Institute, and of Marketing and Strategy from the Centre for Higher Education. Yves Th. Tillet began his professional career in the field of hospital biology and clinical pharmacy. In 1994, Yves Th. Tillet created with and Marie D. White the Cabinet WHITE-TILLET providing expertise in quality, assessment, and regulation of health products. Yves Th. Tillet has taught at several French universities and is author of numerous publications.
Paul is the Head of Smart Devices at Roche / Genentech. Paul has 20 years of experience in medical device R&D, strategic marketing, product management, clinical researc, and medical informatics.
Paul holds four issued patents in medical software and drug delivery devices and multiple patent applications covering software and medical devices. He is also an author and co-author of numerous peer-reviewed articles in medical informatics and diabetes. His educational background includes undergraduate studies in cognitive science and graduate work in health informatics and finance at the University of Minnesota and New York University.
Tom van Ginneken studied chemical engineering in Antwerp and added a MBA from the University of Sankt Gallen to his resume. After working in the chemical and pharmaceutical sector in Belgium for 3 years he joined SCHOTT in 2008.
After different positions in the pharmaceutical product development department he became part of the product management team with focus on the SCHOTT TOPPAC® brand. In this role he works on the strategic orientation and innovation pipeline of the product group.
As Chief Scientist at SiO2 Medical Products, Dr. Weikart is responsible for managing both internal and external R&D initiatives, including collaborative studies at domestic and international universities, customers and research organizations. He oversees the company’s innovation strategy and the development of new technologies for novel, but practical solutions for customer-centric problems. Dr. Weikart works closely with the scientific advisory board and technical consultants for launching new technical initiatives. He also works closely with the intellectual property department to provide technical support for patent filings and trade secret preservation. He is the technical ambassador and spokesman at conferences, regulatory bodies and with customers. Dr. Weikart earned a PhD in chemical engineering from the University of Missouri-Columbia. He worked in Central Research at the Dow Chemical Company for 12 years in various R&D, engineering and leadership roles. Dr. Weikart earned a Six Sigma Black Belt.
Peik-Christian Witte is Director of R&D at Sanner GmbH and responsible for the European R&D activities as well as the entire customer project landscape. Peik has played several roles in technical positions and in different business sectors within R&D and Innovation for more than a decade. He holds an engineering degree in Mechanical Engineering with specialization in Materials Engineering.
